REGENXBIO Archives - Page 2 of 2

November 30, 2023

REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial

REGENXBIO announces that the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE® trial.

November 9, 2023

REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results

On November 9, 2023, REGENXBIO announced financial results for the third quarter ended September 30, 2023, and recent operational highlights, including a strategic pipeline prioritization and corporate restructuring intended to...

October 6, 2023

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

Regenxbio announces interim safety data and initial efficacy data from the Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 for the treatment of Duchenne.

April 12, 2023

REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne

REGENXBIO receives fast track designation for RGX-202 for the treatment of Duchenne

January 23, 2023

REGENXBIO Announces Phase I/II Trial of RGX-202 is Active and Recruiting Duchenne Patients

REGENXBIO announces Phase I/II AFFINITY DUCHENNE trial is active and recruiting patients

Programs

Events